3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
6
Triple Negative Breast Neoplasms
4
Lung Neoplasms
4
Endometrial Neoplasms
3
Breast Neoplasms
3
Neoplasms
2
Neoplasm Metastasis
2
Carcinosarcoma
2
Advanced Solid Tumours
2
Uterine Cervical Neoplasms
1
Thoracic Neoplasms
1
Stomach Neoplasms
1
Solid Tumour Refractory to Conventional Treatment
1
Small Cell Lung Carcinoma
1
Salivary Gland Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Non Small Cell Lung Cancer NSCLC
1
Neoplasms by Site
1
Myelodysplastic Syndromes
1
Melanoma
1
Lung Diseases
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
High Grade Serous Carcinoma
1
Hereditary Sensory and Autonomic Neuropathies
1
Interventions
Carboplatin
5
pembrolizumab
4
Paclitaxel
3
selpercatinib
2
durvalumab
2
Pemetrexed
2
Cisplatin
2
taletrectinib
1
repotrectinib
1
pralsetinib
1
pegylated granulocyte colony-stimulating factor
1
efineptakin alfa
1
ceralasertib
1
cemiplimab
1
atezolizumab
1
Telescopes
1
Radiosurgery
1
Nivolumab
1
Magnetic Resonance Imaging
1
Kyphoplasty
1
Injections, Epidural
1
Gemcitabine
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Thoracic Neoplasms
×
ceralasertib
×
1 year
×
Clear all
NCT05941897
2026-03-05
LOTOS
AstraZeneca
Phase 2
Active not recruiting
39 enrolled